Back to News
Jan 9, 2026 12:00 PM

Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances

Insmed Inc (NASDAQ:INSM) on Friday outlined a commercial and clinical roadmap for 2026, highlighting strong momentum from its respiratory portfolio and a series of upcoming trial readouts and launches that could shape the company's growth over the next 18 months.

• Insmed stock is gaining positive traction. Why are INSM shares climbing?

Speaking ahead of Insmed's presentation at the J.P. Morgan Healthcare Conference, Will Lewis, chair and CEO, said 2025 marked a turning point for the company as it translated scientific advances into commercial execution.

Insmed reported preliminary Brinsupri revenues of $172.7 million for full-year 2025 and approximately $144.6 million for the first full quarter of launch after FDA approval in August 2025.

Brinsupri (brensocatib) is a prescription medicine used to treat non-cystic fibrosis bronchiectasis in patients 12 years of age ...